Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160706 · ClinicalTrials.gov registry record · Phase 3
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 310
- Enrollment target
- 20
- Study locations
NCT00160706: Completed Phase 3 study of Crohn's Disease, sponsored by UCB Pharma.
NCT00160706 is a Phase 3 study of Crohn's Disease that has completed, run by UCB Pharma. The registered enrollment target is 310 participants, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00160706, a Phase 3 study of Crohn's Disease, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 310 participants
- Enrollment target
- 20
- Study locations
Study Summary
A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\] due to an exacerbation of Crohn's Disease.
Primary Outcome
An AE is defined as any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- BIOLOGICAL Certolizumab Pegol (CDP870)
Study Locations (20)
Florida
- 45094 - Gainesville
- 45005 - Hialeah
- 45087 - Miami
- 45004 - North Miami Beach
Alabama
- 45102 - Birmingham
- 45028 - Huntsville
California
- 45095 - Orange
- 45101 - San Francisco
Maryland
- 45033 - Chevy Chase
- 45013 - Laurel
New York
- 45009 - Great Neck
- 45070 - New York
Arkansas
- 45044 - Little Rock
Colorado
- 45130 - Colorado Springs
Illinois
- 45016 - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2004-02 |
| Est. Completion | 2012-05 |
| Phase | Phase 3 |
What the finished NCT00160706 record still lists
NCT00160706 is an interventional study that assigns participants to a tested intervention. The registered 310 participants enrollment target is mid-sized for trials with a published cap, below the 2,392-participant average among 105 other Crohn's Disease trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Certolizumab Pegol (CDP870) is the first listed.
NCT00160706 names 20 study sites across 13 states, led by Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT00160706 about?
NCT00160706 is a clinical study titled "A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's Disease". A follow-on safety study in subjects with Crohn's Disease who have previously been withdrawn from the double-blind study CDP870-031 \[NCT00152490\] or CDP870-032 \[NCT00152425\] due to an exacerbation of Crohn's Disease.
What is the current status of trial NCT00160706?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 310 participants. The study started on 2004-02. Estimated completion is 2012-05.
What conditions does trial NCT00160706 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00160706?
The interventions under investigation include: Certolizumab Pegol (CDP870) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00160706?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00160706 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00160706's enrollment target sits among peer trials
310 35th of 105 higher than 71 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03039439 · 310 participants
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
- NCT04178018 · 310 participants · NA
Transvaginal Ultrasound and Photoacoustic Imaging of Ovary
- NCT04878094 · 310 participants · Phase 3
A Study of Intra-operative Imaging in Women With Ovarian Cancer
- NCT05459233 · 310 participants · NA
Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia